Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Director Sells $201,049.70 in Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT) Director George Kemble sold 20,206 shares of Sagimet Biosciences stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total transaction of $201,049.70. Following the sale, the director owned 62,161 shares in the company, valued at approximately $618,501.95. This trade represents a 24.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

George Kemble also recently made the following trade(s):

• On Monday, July 20th, George Kemble sold 18,844 shares of Sagimet Biosciences stock. The stock was sold at an average price of $7.46, for a total transaction of $140,576.24.

Sagimet Biosciences Stock Up 13.7%

NASDAQ:SGMT opened at $10.55 on Friday. The firm has a market capitalization of $343.77 million, a PE ratio of -8.24 and a beta of 3.37. Sagimet Biosciences Inc. has a 12-month low of $4.50 and a 12-month high of $10.60. The firm has a 50-day moving average price of $7.51 and a 200 day moving average price of $6.57.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). On average, research analysts expect that Sagimet Biosciences Inc. will post -1.15 EPS for the current year.

Sagimet Biosciences News Summary

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne study: The FDA accepted Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of oral, once-daily denifanstat in moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This advances the company’s lead program into a late-stage study and could materially improve its commercial prospects if efficacy and safety are confirmed. FDA Study May Proceed letter and IND clearance
• Positive Sentiment: Citizens JMP raises price target: Citizens JMP increased its target for Sagimet from $12 to $29 and maintained a “Market Outperform” rating. The higher target reflects stronger expectations for denifanstat’s development following the FDA clearance. Citizens JMP price target update
• Positive Sentiment: Additional analyst support: Canaccord Genuity also issued a bullish outlook for SGMT, adding to generally positive Wall Street sentiment around the company’s pipeline and potential future appreciation. Canaccord Genuity Sagimet forecast
• Negative Sentiment: Continued operating losses: Sagimet reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 analyst consensus, while HC Wainwright lowered its fourth-quarter loss estimate to $0.32 per share. The company remains dependent on clinical progress and likely future financing.
• Negative Sentiment: Insider selling: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although the sale may be routine, it could temper investor sentiment following the recent rally. George Kemble insider sale

Institutional Investors Weigh In On Sagimet Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Affinity Asset Advisors LLC raised its position in Sagimet Biosciences by 228.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock valued at $6,798,000 after purchasing an additional 798,245 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Sagimet Biosciences by 6,484.7% during the third quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock worth $5,326,000 after purchasing an additional 788,537 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Sagimet Biosciences in the fourth quarter valued at $4,620,000. Schonfeld Strategic Advisors LLC increased its stake in shares of Sagimet Biosciences by 462.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock valued at $3,593,000 after buying an additional 430,644 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at about $1,802,000. 87.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SGMT. Guggenheim lowered their price target on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Citigroup restated a “market outperform” rating on shares of Sagimet Biosciences in a research note on Friday. Wall Street Zen lowered shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group increased their target price on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.